Guardian Capital Advisors (Canada)’s Teva Pharmaceuticals TEVA Stock Holding History

Guardian Capital Advisors (Canada)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,500	Closed	-$219K	–	169
2016 Q2	$219K	Buy	5,500 +500	+10%	+$26.6K	0.04%	148
2016 Q1	$215K	Hold	5,000	–	–	0.04%	150
2015 Q4	$235K	Hold	5,000	–	–	0.05%	148
2015 Q3	$218K	Sell	5,000 -1,000	-17%	-$64.8K	0.05%	154
2015 Q2	$306K	Hold	6,000	–	–	0.06%	140
2015 Q1	$387K	Hold	6,000	–	–	0.06%	145
2014 Q4	$340K	Buy	+6,000	New	+$334K	0.06%	147
2014 Q3	–	Sell	-6,180	Closed	-$315K	–	177
2014 Q2	$315K	Hold	6,180	–	–	0.06%	156
2014 Q1	$303K	Hold	6,180	–	–	0.06%	154
2013 Q4	$256K	Hold	6,180	–	–	0.05%	155
2013 Q3	$226K	Sell	6,180 -28,480	-82%	-$1.11M	0.05%	154
2013 Q2	$1.33M	Buy	+34,660	New	+$1.35M	0.38%	73

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Guardian Capital Advisors (Canada)'s TEVA Position: Q3 2016 in Review

Guardian Capital Advisors (Canada) sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 5,500 shares — an estimated $219K sold.

Guardian Capital Advisors (Canada) first reported a position in TEVA in Q2 2013 and held it in 12 quarters. The position peaked at $1.33M in Q2 2013. 798 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

Guardian Capital Advisors (Canada) reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Guardian Capital Advisors (Canada) sold 5,500 Teva Pharmaceuticals shares in Q3 2016, an estimated $219K.
Guardian Capital Advisors (Canada) first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 12 quarters.
Guardian Capital Advisors (Canada)'s Teva Pharmaceuticals position peaked at $1.33M in Q2 2013.
798 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Guardian Capital Advisors (Canada)'s 13F filing for Q3 2016, filed 14 Nov 2016.